Equity Investments at a Premium in Biotech Licensings
Executive SummaryAlliance Watch focuses on alliances between established drug firms and public biotechs in which the larger partner bought equity at a premium to the company's average trading price for the 10 days prior to the deal's announcement.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.